Vaxcyte reports Q2 net loss $68.3M, cash $1.44B, VAX-24 infant Phase 2 advanced to Stage 2

Vaxcyte, Inc.

2023-Q2 EPS reported -$1.40

Cash $1.44B as of June 30, includes $545M net from April public offering.
Net loss $68.3M for Q2 2023 vs $48.5M in Q2 2022; R&D expenses $72.7M.
VAX-24 infant Phase 2 advanced to final stage; topline primary data expected by 2025.
VAX-24 adult Phase 2 positive; Phase 3 topline data expected 2025; VAX-31 IND clearance expected Q4 2023.
Board member Michael Kamarck passed away in July 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Vaxcyte, Inc. reported financial results for the second quarter ended June 30, 2023.

Period: the second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 8, 2023, Vaxcyte, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

Vaxcyte, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-039777

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.